跳至主要内容
临床试验/CTRI/2017/11/010340
CTRI/2017/11/010340已完成1 期

Evaluation of the effect of Patrapinda sveda, Tailadhara externally and Panchatiktaka ksheera and ghruta internally in the management of Sandhivata (Osteo arthritis-knee)

Ministry of AYUSH Government of India0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients of either sex with age between 35 and 65 years
  • 2.Patients of primary osteoarthritis knee
  • (Unilateral or bilateral with knee pain >= 14 mm on a 100 mm
  • visual analogue scale and at least 3 of following ACR clinical
  • category diagnostic criteria i.e.,
  • i) Crepitus on active motion
  • ii) less than 30 min of morning stiffness
  • iii) Joint tenderness
  • iv) Joint enlargement
  • v) No palpable warmth of synovium
  • 3. Radiological changes as per Grade I- Grade III of
  • KELLGREN LAWRENCE Radiological scale
  • 4.Able and willing to participate and to provide signed informed consent.

排除标准

  • 1.Patient with Grade IV Kellgren & Lawrence Radiological scale.
  • 2.History of trauma/ fractured joint/ surgical/ diagnostic intervention with reference to the affected joints
  • 3.Patients with co- morbidities such as Gouty Arthritis, Rheumatoid Arthritis and Psoriatic Arthritis.
  • 4.Patients having any deformity of knee, hip or back altering the gait and the posture of the patient.
  • 5.Any unstable cardiovascular disease.
  • 6.Patients who are not ready for IPD admission or for Panchakarma procedures.
  • 7.Patients with ESR level above 35mm/hr
  • 8.Patients with poorly controlled Hypertension ( >160/100 mmHg)
  • 9.Patients with poorly controlled Diabetes Mellitus having HbA1C of > 6.5%
  • 10.Patients on medication with corticosteroids, phototherapy, biologics, antidepressants any other drugs that may have an influence on the outcome of the study.
  • 11.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • 12.Symptomatic patient with clinical evidence of Heart failure.
  • 13.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase(ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary
  • Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study.
  • 14.The Patient has been administered any chondroprotective drugs, intra articular injections into the affected joints or systemic medications with corticosteroids, during the preceding 3 months
  • 15.Alcoholics and/or drug abusers
  • 16.H/o hypersensitivity to any of the trial drugs or their ingredients
  • 17.Pregnant/lactating woman.
  • 18.Patients who have completed participation in any other clinical trial during the past six months.
  • 19.Other conditions which are contraindicated for prescribed treatments.
  • 20.Any other condition which the Investigator thinks may jeopardize the study.

研究者

发起方
Ministry of AYUSH Government of India

相似试验